PR013

PR013 is a novel anti-inflammatory and immunomodulatory topical ocular solution developed for the treatment of allergic conjunctivitis. It has demonstrated efficacy in preclinical models comparable to high-dose steroids in reducing redness (hyperemia) and pruritus associated with allergic conjunctivitis. The drug is being evaluated as a topical ophthalmic drop, with clinical studies including a Phase 2 trial assessing its effectiveness and safety compared to vehicle control in patients with allergic conjunctivitis[2][3][4]. The mechanism of action involves anti-inflammatory and immunomodulatory effects, but the precise molecular target has not been disclosed.